Mark Sausen is an accomplished professional in the field of precision medicine, currently serving as the Head of Technology Innovation at Labcorp since 2022, where they lead the development of genomic sequencing technologies. Mark previously held significant roles at Bristol Myers Squibb, including Scientific Director and Associate Director of Clinical Genetics and Genomics, as well as Vice President of Research and Development at Personal Genome Diagnostics. They earned a Ph.D. in Cellular and Molecular Medicine from Johns Hopkins School of Medicine and a B.A. in Biological and Physical Sciences from the University of Delaware. Mark's extensive experience includes the development and commercialization of innovative cancer diagnostic assays and technologies.
This person is not in any teams
This person is not in any offices